Cargando…

Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4

BACKGROUND: Direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) have drastically improved outcomes but are also very costly. For this reason, priority for treatment is often given to patients with a higher fibrosis score at baseline by payers and providers rather than treatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bach, Timothy A., Zaiken, Kathy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398042/ https://www.ncbi.nlm.nih.gov/pubmed/27882839 http://dx.doi.org/10.18553/jmcp.2016.22.12.1437

Ejemplares similares

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis
por: Yen, Hsu-Heng, et al.
Publicado: (2022)

Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment
por: Lee, Sun Hee, et al.
Publicado: (2020)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
por: Kieran, Jennifer Ann, et al.
Publicado: (2015)

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
por: Wei, Bin, et al.
Publicado: (2018)

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam
por: Nguyen, Dung Thanh, et al.
Publicado: (2020)

Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study
por: Kang, Yeo Wool, et al.
Publicado: (2021)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen, Mohammed, et al.
Publicado: (2017)

Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
por: Toyoda, Hidenori
Publicado: (2019)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
por: Poordad, Fred, et al.
Publicado: (2018)

Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom–Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa( )
por: Aranday-Cortes, Elihu, et al.
Publicado: (2021)

Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages
por: Suenaga, Riichiro, et al.
Publicado: (2021)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Chang, Kao-Chi, et al.
Publicado: (2021)

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
por: Degré, Delphine, et al.
Publicado: (2017)

Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization
por: Pham, Long V., et al.
Publicado: (2022)

Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance
por: Loo, Nicole, et al.
Publicado: (2019)

Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
por: Minosse, Claudia, et al.
Publicado: (2018)

Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C
por: Ramamurthy, Narayan, et al.
Publicado: (2018)

Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5
por: Liu, Chen-Hua, et al.
Publicado: (2022)

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
por: Mölleken, Christian, et al.
Publicado: (2019)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals
por: Lee, Yu-Chi, et al.
Publicado: (2019)

The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals
por: Fayed, Hanan Mahmoud, et al.
Publicado: (2020)

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study
por: Li, Juan, et al.
Publicado: (2020)

Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting
por: Koustenis, Kanellos Rafail, et al.
Publicado: (2020)

Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders
por: Ruiz, Isaac, et al.
Publicado: (2021)

Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus
por: Sy, Aminata, et al.
Publicado: (2023)

Impact of Clinical Pharmacists’ Recommendations on a Proton Pump Inhibitor Taper Protocol in an Ambulatory Care Practice
por: Bundeff, Andrew W., et al.
Publicado: (2013)

Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals
por: Tufan, Ayse Gokcen, et al.
Publicado: (2020)

Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study
por: Li, Wencong, et al.
Publicado: (2022)

Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis
por: Kwo, Paul Y., et al.
Publicado: (2019)

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting
por: Chen, Jian-Hong, et al.
Publicado: (2017)

Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea
por: Ghebremeskel, Ghirmay Ghebrekidan, et al.
Publicado: (2023)

Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China
por: Yun, Haoya, et al.
Publicado: (2020)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Emergence of resistance against direct acting antivirals in chronic HCV patients: A real-world study
por: Majid, Abdul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lon5u8frb1l16r8cqf8r5mkgc5